We are live on
!
Find out more
KCM
Kalehua Capital Management Portfolio holdings
AUM
$174M
This Fund
S&P 500
This Quarter
Est. Return
+9.16%
1 Year Est. Return
–
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$141M
AUM Growth
+$40.2M
(+40%)
Cap. Flow
+$42.1M
Cap. Flow
% of AUM
29.81%
Top 10 Holdings %
Top 10 Hldgs %
72.71%
Holding
28
New
9
Increased
1
Reduced
3
Closed
3
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Gossamer Bio
GOSS
|
+$16.1M |
| 2 |
MANE
Veradermics Inc
MANE
|
+$7.35M |
| 3 |
Aclaris Therapeutics
ACRS
|
+$6.18M |
| 4 |
uniQure
QURE
|
+$5.89M |
| 5 |
PepGen
PEPG
|
+$5.62M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Allogene Therapeutics
ALLO
|
+$3.49M |
| 2 |
Oric Pharmaceuticals
ORIC
|
+$2.18M |
| 3 |
Verrica Pharmaceuticals
VRCA
|
+$1.96M |
| 4 |
Alpha Architect 1-3 Month Box ETF
BOXX
|
+$1.45M |
| 5 |
DiaMedica Therapeutics
DMAC
|
+$260K |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 81.79% |
| 2 | Materials | 0.26% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
1
Alpha Architect 1-3 Month Box ETF
BOXX
$14B
| $25.4M | 17.96% |
218,278
-12,509
| -5% | -$1.45M |
|
2
X4 Pharmaceuticals
XFOR
$402M
| $15.4M | 10.88% |
3,722,840
| – | – |
|
3
Surrozen
SRZN
$282M
| $11.2M | 7.94% |
385,178
| – | – |
|
|
MANE
4
Veradermics Inc
MANE
$4.11B
| $9.2M | 6.51% |
+145,695
| New | +$7.35M |
|
5
Relay Therapeutics
RLAY
$4.33B
| $8.97M | 6.35% |
901,457
| – | – |
|
|
SION
6
Sionna Therapeutics
SION
$253M
| $7.9M | 5.59% |
197,072
| – | – |
|
|
7
Aclaris Therapeutics
ACRS
$929M
| $6.87M | 4.86% |
+1,832,365
| New | +$6.18M |
|
8
Inhibikase Therapeutics
IKT
$349M
| $6.42M | 4.54% |
3,821,890
+2,071,890
| +118% | +$3.68M |
|
|
ORKA
9
Oruka Therapeutics
ORKA
$6.78B
| $5.81M | 4.11% |
118,524
| – | – |
|
10
Pharvaris
PHVS
$2.62B
| $5.62M | 3.97% |
198,772
| – | – |
|
|
11
uniQure
QURE
$3.29B
| $4.76M | 3.37% |
+291,109
| New | +$5.89M |
|
|
SEPN
12
Septerna Inc
SEPN
$1.89B
| $4.67M | 3.31% |
194,544
| – | – |
|
|
CMPS
13
Compass Pathways
CMPS
$1.97B
| $4.53M | 3.21% |
819,692
| – | – |
|
|
LONA
14
LeonaBio Inc
LONA
$72.8M
| $4.05M | 2.86% |
393,701
| – | – |
|
|
DMRA
15
Damora Therapeutics
DMRA
$1.87B
| $3.6M | 2.55% |
+139,000
| New | +$3.57M |
|
|
16
Gossamer Bio
GOSS
$85.5M
| $3.36M | 2.38% |
+10,236,293
| New | +$16.1M |
|
17
MoonLake Immunotherapeutics
MLTX
$1.31B
| $3.28M | 2.32% |
175,734
| – | – |
|
18
Tyra Biosciences
TYRA
$1.56B
| $2.85M | 2.02% |
74,465
| – | – |
|
|
19
PepGen
PEPG
$221M
| $1.77M | 1.25% |
+1,000,000
| New | +$5.62M |
|
20
Instil Bio
TIL
$53M
| $1.51M | 1.07% |
+183,030
| New | +$1.48M |
|
21
Tenaya Therapeutics
TNYA
$151M
| $1.38M | 0.98% |
2,000,000
| – | – |
|
22
Korro Bio
KRRO
$192M
| $1.24M | 0.88% |
+109,376
| New | +$1.2M |
|
|
KLRS
23
Kalaris Therapeutics
KLRS
$97.6M
| $782K | 0.55% |
135,585
-4,316
| -3% | -$38.3K |
|
|
24
DiaMedica Therapeutics
DMAC
$352M
| $423K | 0.3% |
62,488
-32,871
| -34% | -$260K |
|
25
Loop Industries
LOOP
$29.9M
| $361K | 0.26% |
+347,539
| New | +$436K |
|
Similar funds
PWSG
6SA
NWA
PIA
CPCP
PMSA
MCM
AIA
Kalehua Capital Management's Q1 2026 Portfolio in Review
As of Q1 2026, Kalehua Capital Management held 28 positions worth $141M, up 40% from $101M the previous quarter. Its ten largest holdings account for 73% of the portfolio.
Kalehua Capital Management deployed $42.1M of net new capital in Q1 2026, opening 9 new positions and adding to 1 existing holding. Its largest new stake was Gossamer Bio: 10,236,293 shares worth $3.36M.
By sector, the portfolio is most concentrated in Healthcare at 82% of assets, up from 74% a quarter earlier, followed by Materials.
On the sell side, the largest reduction was Alpha Architect 1-3 Month Box ETF, an estimated $1.45M trimmed.
- Kalehua Capital Management's largest Q1 2026 buy was Gossamer Bio: 10,236,293 shares worth $3.36M.
- Kalehua Capital Management added most to Inhibikase Therapeutics in Q1 2026, an estimated $3.68M increase.
- Kalehua Capital Management's biggest Q1 2026 reduction was Alpha Architect 1-3 Month Box ETF, cutting an estimated $1.45M.
- Kalehua Capital Management fully exited Allogene Therapeutics in Q1 2026, selling an estimated $3.49M.
- Kalehua Capital Management's ten largest holdings make up 73% of its $141M portfolio in Q1 2026.
- Kalehua Capital Management opened 9 new positions and closed 3 in Q1 2026.
- Kalehua Capital Management's portfolio value rose 40% quarter-over-quarter to $141M.
Based on Kalehua Capital Management's 13F filing for Q1 2026, filed 15 May 2026.